Advanced search
Publication Cover
Immunotherapy Volume 12, 2020 - Issue 7
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Case Report

PD-1 Blockade for Disseminated Kaposi Sarcoma in a Patient with Atopic Dermatitis and Chronic CD8 Lymphopenia

Thilo Gambichler1 Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7862-3695
ORCID Icon &
Laura Susok1 Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
Pages 451-457 | Received 12 Oct 2019, Accepted 03 Apr 2020, Published online: 22 Apr 2020

References

  • Deylon J , BizotA , BattistellaM , MadelaineI , VercellinoL , LebbéC. PD-1 blockade with nivolumab in endemic Kaposi sarcoma. Ann. Oncol.29(4), 1067–1069 (2018).
  • Uldrick TS , GonçalvesPH , Abdul-HayMet al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer - a Phase I study. JAMAOncol. doi:10.1001/jamaoncol.2019.2244 (2019) ( Epub ahead of print).
  • Galanina N , GoodmanAM , CohenPR , FramptonGM , KurzrockR. Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade. Cancer Immunol. Res.6(10), 1129–1135 (2018).
  • Cook MR , KimC. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol.5(7), 1049–1054 (2019).
  • Yarmohammadi H , Cunningham-RundlesC. Idiopathic CD4 lymphocytopenia: pathogenesis, etiologies, clinical presentations and treatment strategies. Ann. Allergy Asthma Immunol.119(4), 374–378 (2017).
  • Tavakol M , JameeM , AziziGet al. Diagnostic approach to the patients with suspected primary immunodeficiency. Endocr. Metab. Immune Disord. Drug Targets doi:10.2174/1871530319666190828125316 (2019) ( Epub ahead of print).
  • Lebbe C , GarbeC , StratigosAJet al. Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur. J. Cancer114, 117–127 (2019).
  • Salem HA , ElSohafy M , AbdEl Gawad M. Kaposi’s sarcoma in an atopic dermatitis patient: a case report and a review of literature. Pediatr. Dermatol.28(5), 547–549 (2011).
  • Wall D , McMenaminM , O'MahonyD , IrvineAD. Kaposi sarcoma in a patient with atopic dermatitis treated with ciclosporin. BMJ Case Rep.pii: bcr20132021712013) ( Epub ahead of print).
  • Vandercam B , LachapelleJM , JanssensP , TennstedtD , LambertM. Kaposi’s sarcoma during immunosuppressive therapy for atopic dermatitis. Dermatology194(2), 180–182 (1997).
  • Kreuter A , BischoffS , SkryganMet al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides. Arch. Dermatol.144(8), 1011–1016 (2008).
  • Goodrich AL , TigelaarRE , WatskyKL , HealdPW. Idiopathic CD4+ lymphocyte deficiency. Report of an unusual case associated with atopic dermatitis and allergic contact dermatitis and review of the literature. Arch. Dermatol.129(7), 876–878 (1993).
  • Gergely P . Drug-induced lymphopenia: focus on CD4+ and CD8+ cells. Drug Saf.21(2), 91–100 (1999).
  • Tornatore KM , VenutoRC , LogueG , DavisPJ. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. J. Med.29(3-4), 159–183 (1998).
  • Schneider JW , DittmerDP. Diagnosis and treatment of Kaposi sarcoma. Am. J. Clin. Dermatol.18(4), 529–539 (2017).
  • Saller J , WalkoCM , MillisSZ , Henderson-JacksonE , MakanjiR , BrohlAS. Response to checkpoint inhibitor therapy in advanced classic Kaposi sarcoma: a case report and immunogenomic study. J. Natl Compr. Canc. Netw.16(7), 797–800 (2018).
  • Deylon J , ArangalageD , BaroudjianB , LebbeC. Letter to the editor: could immunogenicity of Kaposi sarcoma be more linked to viral antigens than to the tumor mutational burden?J. Natl Compr. Canc. Netw.16(12), 1418–1419 (2018).
  • Chen J , DelValle L , LinHYet al. Expression of PD-1 and PD-Ls in Kaposi’s sarcoma and regulation by oncogenic herpesvirus lytic reactivation. Virology536, 16–19 (2019).
  • Maleki Vareki S . High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer6(1), 157 (2018).
  • Gambichler T , KoimS , WrobelMet al. Expression of programmed cell death proteins in Kaposi sarcoma and cutaneous angiosarcoma. J. Immunother. doi:10.1087/CJI.0000000000000317 (2020). (Epub ahead of print).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.